The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Brady W. Dougan net worth and biography

Brady Dougan Biography and Net Worth

Director of Humacyte
Mr. Dougan served as the chair of the Humacyte Board from March 2019 to August 2021, and as a member of its Board of Directors since 2005. Mr. Dougan holds a B.A. in Economics and an M.B.A. in Finance from the University of Chicago. Mr. Dougan has been a member of Humacyte’s Board since the Company’s founding.

What is Brady W. Dougan's net worth?

The estimated net worth of Brady W. Dougan is at least $50.01 million as of December 16th, 2022. Mr. Dougan owns 17,990,736 shares of Humacyte stock worth more than $50,014,246 as of January 30th. This net worth estimate does not reflect any other assets that Mr. Dougan may own. Learn More about Brady W. Dougan's net worth.

How do I contact Brady W. Dougan?

The corporate mailing address for Mr. Dougan and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected] Learn More on Brady W. Dougan's contact information.

Has Brady W. Dougan been buying or selling shares of Humacyte?

Brady W. Dougan has not been actively trading shares of Humacyte during the past quarter. Most recently, Brady W. Dougan sold 239,538 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $2.53, for a transaction totalling $606,031.14. Following the completion of the sale, the director now directly owns 17,990,736 shares of the company's stock, valued at $45,516,562.08. Learn More on Brady W. Dougan's trading history.

Who are Humacyte's active insiders?

Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.

Are insiders buying or selling shares of Humacyte?

During the last twelve months, Humacyte insiders bought shares 7 times. They purchased a total of 51,525 shares worth more than $192,428.00. During the last twelve months, insiders at the sold shares 5 times. They sold a total of 2,461,768 shares worth more than $8,641,540.56. The most recent insider tranaction occured on December, 16th when CFO Dale A Sander bought 20,000 shares worth more than $52,000.00. Insiders at Humacyte own 25.0% of the company. Learn More about insider trades at Humacyte.

Information on this page was last updated on 12/16/2022.

Brady W. Dougan Insider Trading History at Humacyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Sell239,538$2.53$606,031.1417,990,736View SEC Filing Icon  
12/14/2022Sell276,304$2.76$762,599.0418,323,700View SEC Filing Icon  
9/15/2022Sell1,522,500$4.00$6,090,000.0018,930,004View SEC Filing Icon  
12/16/2021Sell75,000$9.00$675,000.00View SEC Filing Icon  
12/14/2021Sell100,000$9.44$944,000.00View SEC Filing Icon  
See Full Table

Brady W. Dougan Buying and Selling Activity at Humacyte

This chart shows Brady W Dougan's buying and selling at Humacyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humacyte Company Overview

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $2.78
Low: $2.61
High: $2.81

50 Day Range

MA: $2.63
Low: $2.02
High: $3.27

2 Week Range

Now: $2.78
Low: $1.96
High: $8.04

Volume

210,100 shs

Average Volume

211,617 shs

Market Capitalization

$286.67 million

P/E Ratio

8.69

Dividend Yield

N/A

Beta

1.13
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.